P53-dependent DNA Damage-induced Apoptosis Requires Fas/APO-1-independent Activation of CPP32beta
Overview
Authors
Affiliations
In many cell types, the p53 tumor suppressor protein is required for the induction of apoptosis by DNA-damaging chemotherapy or radiation. Therefore, identification of the molecular determinants of p53-dependent cell death may aid in the design of effective therapies of p53-deficient cancers. We investigated whether p53-dependent apoptosis requires activation of CPP32beta (caspase 3), a cysteine protease that has been found to mediate apoptosis in response to ligation of the Fas molecule or to granzyme B, a component of CTL lytic granules. Irradiation-induced apoptosis was associated with p53-dependent activation of CPP32beta-related proteolysis, and normal thymocytes were protected from irradiation by Acetyl-Asp-Glu-Val-Asp-CHO (Ac-DEVD-CHO), a specific inhibitor of CPP32beta. We next examined whether the Fas system is required for p53-dependent apoptosis and whether stimuli that induce activation of CPP32beta induce apoptosis in p53-deficient cells. Thymocytes or activated T cells from Fas-deficient mice were resistant to apoptosis induced by ligation of Fas or CD3, respectively, but remained normally susceptible to irradiation. Thymocytes from p53-deficient mice, although resistant to DNA damage, remained sensitive to CPP32beta-mediated apoptosis induced by ligation of Fas or CD3, or by exposure to cytotoxic T cells. These results demonstrate that DNA damage-induced apoptosis of T cells requires p53-mediated activation of CPP32beta by a mechanism independent of Fas/FasL interactions and suggest that immunological or molecular methods of activating CPP32beta may be effective at inducing apoptosis in p53-deficient cancers that are resistant to conventional chemotherapy or irradiation.
Ahmed O, Fahim H, Ahmed H, Al-Muzafar H, Ahmed R, Amin K Oxid Med Cell Longev. 2019; 2019:2745352.
PMID: 31049130 PMC: 6458942. DOI: 10.1155/2019/2745352.
p53-Pirh2 Complex Promotes Twist1 Degradation and Inhibits EMT.
Yang-Hartwich Y, Tedja R, Roberts C, Goodner-Bingham J, Cardenas C, Gurea M Mol Cancer Res. 2018; 17(1):153-164.
PMID: 30131448 PMC: 6800184. DOI: 10.1158/1541-7786.MCR-18-0238.
Oridonin increases anticancer effects of lentinan in HepG2 human hepatoblastoma cells.
Sun Z, Han Q, Duan L, Yuan Q, Wang H Oncol Lett. 2018; 15(2):1999-2005.
PMID: 29434900 PMC: 5774387. DOI: 10.3892/ol.2017.7485.
Xu T, Jin F, Wu K, Ye Z, Li N Exp Ther Med. 2017; 14(5):5129-5134.
PMID: 29201227 PMC: 5704296. DOI: 10.3892/etm.2017.5168.
Murakoshi M, Osamura R Acta Histochem Cytochem. 2017; 50(2):57-61.
PMID: 28522880 PMC: 5433935. DOI: 10.1267/ahc.17010.